Back to all time high as it is 30 minutes ago until the start of trading. I'm Dani Burger and I'm Michael McKee. Bloomberg.Open interest starts right now. Coming up on the show, the S&P extends its winning streak even as sky high eye spending since space Ken Griffin Citadel is already cashing in on its bargain bet on situational awareness and Wall Street banker bonuses are set to climb yet again as volatile markets boost profits. Speaking of those volatile markets, let's look at space now.It is down 11.3% i ...

The company smashed estimates for the quarter and hiked its revenue outlook once again. It now expects sales of 85 billion to 87 billion, up from a previous outlook of 82 billion to 85 billion. Sales jumped 48% this quarter thanks to higher demand for Zepbound and Munjaro, which helped offset those lower prices of those treatments in the US.And Munjara almost topped 10 billion in sales for the first time. And we're seeing strong demand for that drug internationally. One thing I'll highlight is that this is ...

And I think the best news here about the oral category is it's really expansionary. It's not cannibalizing Zepbound. In fact, Zepbound actually accelerated during these oral launches uh with new starts and our and our market share there.So, um I think the big concern last year from the street was how much growth could there be. Uh is this just a business where people going to cycle on and off the therapies. Is it limited by insurance.I think what we're seeing in the first half of this year and with Lily's r ...

5 Hidden Side Effects Of GLP-1s To Consider Before Treatment https://t.co/0VUiDA0SGRPhoto: Getty Images https://t.co/7MWHz5AG2r ...

a few things that the market is focusing on. One thing is the WGOI pill. Of course, this was a monster launch a couple months ago.It's going extremely well, but according to analyst expectations, it could have gone better maybe. What's going on here. >> I actually take that little bit as a compliment because they've done so well that probably some analysts out there have raised their expectations even more.Actually many of those analysts used to think that by the time the Viggoi pill gets competition from o ...

Eli Lilly raised its 2026 sales guidance after it reported far stronger second-quarter demand than analysts estimated for its weight-loss and diabetes drugs https://t.co/YRTveVO8XX ...

Abdul El-Sayed, the progressive former public health official and likely nominee in the Michigan Democratic Senate primary race, says on Morning Joe that Medicare for All is the “cause of my career in public service.” He then condemns the pharmaceutical and insurance industries for “nickel-and-diming politicians” before repeating his campaign message of going after money in politics. MS NOW: My Source for News, Opinion, and the World. » Subscribe to MS NOW: https://www.youtube.com/@msnow » Subscribe to MS N ...

Eli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs. https://t.co/7EBhfBVKEe ...

>> NEWSMAKERS AND MARKET MOVERS, THIS IS "THE PULSE" WITH FRANCINE LACQUA. FRANCINE: GOOD MORNING AND WELCOME. I'M FRANCINE LACQUA IN LONDON.GLOBAL STOCKS SET A NEW RECORD WITH AI AND RENEWED HOPES OF A MIDDLE EAST DEAL LIFTING OPTIMISM. WE WILL DISCUSS ALL OF THAT IN A SECOND BUT START WITH SPACEX WHICH IS UNDER PRESSURE THIS MORNING AFTER IT IS CLOSED HIGHER THAN EXPECTED SPENDING ON ITS AI BUSINESS. THAT HAS DAMPENED A REPORT THAT BROADLY SURPASSED WALL STREET FORECAST.ELON MUSK ALSO OUTLINED PLANS TO SI ...

Sandoz CEO Richard Saynor said the move by US President Donald Trump to potentially impose tariffs on generic medicines is more of an opportunity than a threat to its business https://t.co/U8DiKlYKo6 ...